Ribupatide: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข3 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Storage conditions have not been publicly disclosed. As a peptide-based injectable, refrigerated storage at 2-8 degrees C is expected for the injectable formulation.
Protocol Quick-Reference
Chronic weight management in adults with obesity
Dosing
Amount
Up to 8 mg (injectable) or 10-50 mg (oral)
Frequency
Once weekly (injectable) or once daily (oral)
Duration
26-36 weeks (Phase 2 trials)
Administration
Route
SCSchedule
Once weekly (injectable formulation)
Timing
Dose escalation used to minimize GI side effects. Both injectable and oral formulations are under investigation.
Cycle
Duration
36 weeks (injectable Phase 2)
Repeatable
Yes
โ๏ธ Suggested Bloodwork (4 tests)
Fasting blood glucose and HbA1c
When: Baseline
Why: Baseline metabolic assessment
Lipid panel
When: Baseline
Why: Baseline cardiovascular risk factors
CMP (Comprehensive Metabolic Panel)
When: Baseline and 12 weeks
Why: Monitor liver and kidney function
Fasting blood glucose and HbA1c
When: 12 weeks
Why: Monitor metabolic response
๐ก Key Considerations
- โInvestigational compound not approved by any regulatory agency; available only in clinical trials
- โGI adverse events (nausea, vomiting, diarrhea) are common with GLP-1/GIP agonists; dose escalation mitigates this
- โNo cardiovascular outcomes data or long-term safety data available
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Weight Management (Injectable Phase 2) | Dose escalation to 8 mg once weekly subcutaneous injection over 36 weeks. | Once weekly subcutaneous injection | 36 weeks (Phase 2 trial) | The 8 mg dose achieved 22.8% mean weight loss (21.1% placebo-adjusted) at 36 weeks. 59% of participants achieved 20% or more weight loss. No plateau was observed at end of treatment. |
| Weight Management (Oral Phase 2, China) | 10 mg, 25 mg, or 50 mg once daily oral tablet. | Once daily oral | 26 weeks (Phase 2 trial) | Mean weight loss of 6.9% (10 mg), 12.1% (25 mg), and 12.1% (50 mg) versus 2.3% placebo at 26 weeks. Up to 38.6% of participants on oral ribupatide achieved at least 15% weight loss. |
| Weight Management (Injectable Phase 3, China) | Dose escalation with HRS9531 once weekly subcutaneous injection. | Once weekly subcutaneous injection | Phase 3 ongoing | Hengrui has completed Phase 3 obesity trials in China and reported additional data showing significant weight loss results. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Ribupatide is an investigational compound available only in clinical trials. The injectable formulation is administered as a subcutaneous injection. The oral formulation is taken as a tablet. No reconstitution is required for either formulation.
Recommended Injection Sites
- โAbdomen
- โThigh
- โUpper arm
๐งStorage Requirements
Storage conditions have not been publicly disclosed. As a peptide-based injectable, refrigerated storage at 2-8 degrees C is expected for the injectable formulation.
Community Dosing Protocols
Compare these clinical doses with what community members report using.
0View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Investigational Status#
Ribupatide (HRS9531/KAI-9531) is an investigational drug in Phase 2/3 clinical trials. It is not approved by any regulatory authority and is not available outside of clinical trials. All dosing information is derived from published clinical trial data.
Injectable Formulation Dosing#
Phase 2 Trial Results (8 mg Dose)#
The Phase 2 injectable trial evaluated once-weekly subcutaneous ribupatide at the 8 mg dose in adults with overweight or obesity without type 2 diabetes over 36 weeks.
| Endpoint | 8 mg Injectable | Placebo |
|---|---|---|
| Mean weight loss | 22.8% | 1.7% |
| Placebo-adjusted weight loss | 21.1% | - |
| Achieved 20% or more weight loss | 59% | Not reported |
| Weight loss plateau | Not observed | - |
The dose escalation schedule for the injectable formulation has not been fully disclosed in publicly available data. Consistent with other GLP-1/GIP agonists, a gradual escalation to the maintenance dose is expected to minimize gastrointestinal side effects.
Phase 3 KaiNETIC Program (Global)#
Kailera Therapeutics has initiated the global Phase 3 KaiNETIC program for injectable ribupatide. Specific dose selections and escalation schedules for the Phase 3 program have not been publicly disclosed.
Oral Formulation Dosing#
Phase 2 Trial Results (China)#
The oral Phase 2 trial (HRS9531-T-201) enrolled 166 participants in China with obesity (BMI 28 kg/m2 or above) without type 2 diabetes. Participants were randomized to once-daily oral ribupatide at 10 mg, 25 mg, or 50 mg, or placebo for 26 weeks.
| Dose | Weight Loss at 26 Weeks | Achieved 15% or More |
|---|---|---|
| 10 mg daily | 6.9% | Lower proportion |
| 25 mg daily | 12.1% | Intermediate |
| 50 mg daily | 12.1% | Up to 38.6% |
| Placebo | 2.3% | - |
No weight loss plateau was observed at 26 weeks in any active treatment arm, suggesting continued efficacy with longer treatment.
Oral Formulation Advancement#
Based on the Phase 2 results, Hengrui is advancing once-daily oral ribupatide to Phase 3 in China, and Kailera plans to initiate a global Phase 2 trial in 2026.
Administration#
Injectable#
Administered once weekly via subcutaneous injection, consistent with other GLP-1/GIP agonist peptides. Injection sites include abdomen, thigh, and upper arm with site rotation.
Oral#
The oral tablet is taken once daily. Specific administration requirements (fasting, water restrictions) have not been publicly disclosed but may be similar to other oral peptide formulations that require fasting conditions for optimal absorption.
Dosing Context#
Ribupatide belongs to the Metabolic category of research peptides. Dosing protocols for Ribupatide are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.
Research Protocols#
The following dosing protocols have been documented in clinical research for Ribupatide:
Weight Management (Injectable Phase 2)#
Dose: Dose escalation to 8 mg once weekly subcutaneous injection over 36 weeks.
Frequency: Once weekly subcutaneous injection
Duration: 36 weeks (Phase 2 trial)
The 8 mg dose achieved 22.8% mean weight loss (21.1% placebo-adjusted) at 36 weeks. 59% of participants achieved 20% or more weight loss. No plateau was observed at end of treatment.
Weight Management (Oral Phase 2, China)#
Dose: 10 mg, 25 mg, or 50 mg once daily oral tablet.
Frequency: Once daily oral
Duration: 26 weeks (Phase 2 trial)
Mean weight loss of 6.9% (10 mg), 12.1% (25 mg), and 12.1% (50 mg) versus 2.3% placebo at 26 weeks. Up to 38.6% of participants on oral ribupatide achieved at least 15% weight loss.
Weight Management (Injectable Phase 3, China)#
Dose: Dose escalation with HRS9531 once weekly subcutaneous injection.
Frequency: Once weekly subcutaneous injection
Duration: Phase 3 ongoing
Hengrui has completed Phase 3 obesity trials in China and reported additional data showing significant weight loss results.
Reconstitution and Preparation#
Ribupatide is an investigational compound available only in clinical trials. The injectable formulation is administered as a subcutaneous injection. The oral formulation is taken as a tablet. No reconstitution is required for either formulation.
Injection Sites#
Recommended injection sites for Ribupatide include:
- Abdomen
- Thigh
- Upper arm
Site rotation is recommended to minimize local tissue reactions and ensure consistent absorption.
Storage Requirements#
Storage conditions have not been publicly disclosed. As a peptide-based injectable, refrigerated storage at 2-8 degrees C is expected for the injectable formulation.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Ribupatide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.